Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Danish regulators have raised concerns about a rare eye disease associated with Novo Nordisk's GLP-1 drug, Ozempic, prompting a request for a formal EU review. The FTC has approved Novo Holdings' acquisition of Catalent, allowing the deal to proceed. Bristol Myers Squibb is aiming to reduce costs by $1.5 billion by 2025, while PepGen is facing an FDA hold on its Duchenne muscular dystrophy treatment trial. Intelligencia AI's accurate pre-ASH predictions for biotechs demonstrate the reliability of their AI methodology.In other news, there are advancements in molecular glue degraders, AbbVie continues its deal-making spree, Novo Nordisk reaffirms its commitment to a rare disease production facility, and there are ongoing challenges with drugs targeting the amyloid hypothesis. Layoffs at Editas and FDA approvals for Neurocrine and Checkpoint are also making headlines.